(Q44115945)

English

Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in 'real world' patients with chronic hepatitis C.

scientific article published in September 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12197842%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in 'real world' patients with chronic hepatitis C (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12197842%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12197842%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

author name string

G B Gaeta

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12197842%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

D F Precone

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12197842%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

F M Felaco

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12197842%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

A Spadaro

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12197842%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

G Stornaiuolo

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12197842%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

M Stanzione

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12197842%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

T Ascione

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12197842%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

R De Sena

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12197842%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

A Campanone

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12197842%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

G Filice

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12197842%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

F Piccinino

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12197842%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

language of work or name

0 references

publication date

1 September 2002

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12197842%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Alimentary Pharmacology & Therapeutics

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12197842%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12197842%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12197842%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

1633-1639

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12197842%20AND%20SRC:MED&resulttype=core&format=json

12 November 2019

Pathogenesis, natural history, treatment, and prevention of hepatitis C.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01331.X

21 January 2018

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01331.X

21 January 2018

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01331.X

21 January 2018

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01331.X

21 January 2018

Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01331.X

21 January 2018

Antiviral therapy for patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01331.X

21 January 2018

A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01331.X

21 January 2018

Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01331.X

21 January 2018

Ribavirin uptake by human erythrocytes and the involvement of nitrobenzylthioinosine-sensitive (es)-nucleoside transporters

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01331.X

21 January 2018

Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01331.X

21 January 2018

Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01331.X

21 January 2018

A preliminary study of erythropoietin for anemia associated with ribavirin and interferon-alpha

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01331.X

21 January 2018

Management strategies for ribavirin-induced hemolytic anemia in the treatment of hepatitis C: clinical and economic implications

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01331.X

21 January 2018

Factors influencing ribavirin-induced hemolysis

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01331.X

21 January 2018

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01331.X

21 January 2018

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01331.X

21 January 2018

A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01331.X

21 January 2018

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01331.X

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44115945&oldid=2106739135"